Vertex Pharmaceuticals

Yahoo Finance • 5 hours ago

Key deals this week: KORE, TopBuild, Equinix, PayPal and more

[M A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] fengdr Here's a list of key deals reported across sectors this week: * KORE Group Holdings (KORE [https://seekingalpha.com/symbol/KORE]) on Friday... Full story

Yahoo Finance • 10 hours ago

Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory

We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.'s share was trading at $12.48 as of February 18th.... Full story

Yahoo Finance • 12 hours ago

Sana Biotechnology, Inc. (SANA): A Bull Case Theory

We came across a bullish thesis on Sana Biotechnology, Inc. on Stock Invader’s Substack. In this article, we will summarize the bulls’ thesis on SANA. Sana Biotechnology, Inc.'s share was trading at $4.00 as of February 9th.Why Impact Biom... Full story

Yahoo Finance • 4 days ago

2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustai... Full story

Yahoo Finance • 5 days ago

The Ultimate Biotech Stock to Buy With $500 Right Now

Biotech companies are all about innovation. These players are developing and using cutting-edge technologies to address a variety of diseases, and in many cases, their efforts are leading to game-changing products for patients. You can inv... Full story

Yahoo Finance • 6 days ago

Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036?

Turning $100,000 into $1 million in a decade requires a compound annual growth rate (CAGR) of almost 26%. That's miles above the market's long-term average. It's also even better than a company like Vertex Pharmaceuticals(NASDAQ: VRTX), an... Full story

Yahoo Finance • 8 days ago

The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics(NASDAQ: CRSP), is the real buy for long-term investors. Shares of Vertex, a biotech based in Boston, popped last week after it re... Full story

Yahoo Finance • 14 days ago

Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Vertex Pharmaceuticals (NasdaqGS:VRTX) has signed a license and research agreement with WuXi Biologics for a trispecif... Full story

Yahoo Finance • 14 days ago

Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI

Evercore ISI raised the firm’s price target on Crispr Therapeutics (CRSP) to $74 from $62 and keeps an Outperform rating on the shares. The updated target reflects strong momentum as Vertex Pharmaceuticals’ (VRTX) new guidance for Casgevy... Full story

Yahoo Finance • 15 days ago

Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with an Overweight rating and a $... Full story

Yahoo Finance • 15 days ago

Stock Market Today: Dow Slips After CPI Inflation Surprise; DraftKings Plunges On Earnings (Live Coverage)

Stock Market Today: The Dow Jones index dropped Friday on a surprise CPI inflation report. DraftKings plunged on earnings. Continue Reading... Full story

Yahoo Finance • 16 days ago

Vertex outlines 8% to 9% revenue growth for 2026 as non-CF products gain momentum

Earnings Call Insights: Vertex Pharmaceuticals Incorporated (VRTX) Q4 2025 MANAGEMENT VIEW * CEO Reshma Kewalramani highlighted "excellent progress across the business, disciplined commercial execution in CF and the new product launche... Full story

Yahoo Finance • 16 days ago

Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its fourth quarter that Increases, from last year The company's earnings came in at $1.191 billion, or $4.65 per share. This compares with $913.0 million, or $3.50 per... Full story

Yahoo Finance • 16 days ago

Stock Market Today, Feb. 12: Stocks moderate as initial claims fall, continuing claims rise

This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Thursday. This is TheStreet’s Stock Market Today for Feb. 12, 2026. You c... Full story

Yahoo Finance • 18 days ago

Should You Buy Vertex Before Feb. 12?

Vertex Pharmaceuticals(NASDAQ: VRTX) has underperformed the market over the past year, rising less than 2%. The biotech, known for its cystic fibrosis (CF) treatments, is scheduled to report earnings on Feb. 12. While there's never just on... Full story

Yahoo Finance • 19 days ago

Should You Buy Vertex Pharmaceuticals Before Feb. 12?

Key Points Vertex's core franchise probably won't lead to any surprises, but newer launches could. The company should see significant pipeline progress this year. Vertex looks like a strong buy-and-hold option. 10 stocks we like better t... Full story

Yahoo Finance • 19 days ago

Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million

Precedence Research Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company performance, pipeline developments, and gover... Full story

Yahoo Finance • 21 days ago

2 Top Healthcare Stocks to Buy in February

After underperforming broader equities over the past few years, will the healthcare sector finally rebound and deliver above-average returns from here on out? That's hard to say. Whatever the case, there are plenty of attractive healthcare... Full story

Yahoo Finance • 24 days ago

Software stocks take hit on AI. Is Wall Street worried of a bubble?

A sell-off storm brewed over software stocks in Tuesday's session over growing AI concerns tied to Anthropic's (ANTH.PVT) new AI chatbot Claude. Lossdog Founder and CEO Tom Sosnoff and Yahoo Finance Senior Reporter Brooke DiPalma break do... Full story

Yahoo Finance • 25 days ago

These Are The Worst 25 Stocks to Own in February

It's been an interesting start to the year, with plenty of geopolitical developments for investors to unpack. The market managed monthly wins in January, but as we get into February, it's not a bad idea to keep an eye on stocks that have h... Full story